Blend takes a novel approach to cancer treatment by creating Pentarins™, which are miniaturized biologic drug conjugates uniquely designed to target, penetrate and treat solid tumors.
Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors. Pentarins penetrate deep into solid tumors and attack the cancer cells with highly selective targeting and potent payloads.
Blend’s first Pentarin, PEN-221, is a novel cancer therapeutic that is highly selective for the somatostatin receptor. PEN-221 is being developed to treat neuroendocrine cancers including small cell lung cancer.